Ligand Announces OmniAb Partnership with iMetabolic Biopharma

Pharmaceutical Investing

Ligand Pharmaceuticals (NASDAQ:LGND) announces it has entered into a worldwide OmniAb partnership with iMetabolic Biopharma (iMBP), an early stage biopharma company located in Tempe, AZ. Under the terms of the partnership, iMBP gains access to the full OmniAb platform including OmniRat, OmniMouse, OmniFlic and OmniChicken in their drug discovery efforts. As quoted in the press release: “Ligand is …

Ligand Pharmaceuticals (NASDAQ:LGND) announces it has entered into a worldwide OmniAb partnership with iMetabolic Biopharma (iMBP), an early stage biopharma company located in Tempe, AZ. Under the terms of the partnership, iMBP gains access to the full OmniAb platform including OmniRat, OmniMouse, OmniFlic and OmniChicken in their drug discovery efforts.

As quoted in the press release:

“Ligand is proud of its heritage of establishing strategic partnerships with innovative, emerging organizations with experienced management teams, and our agreement with iMetabolic Biopharma Corporation is another example of such an alliance,” said John Higgins, Chief Executive Officer of Ligand. “Like our many other OmniAb partners, iMBP understands the value and benefit of the multi-species, genetically engineered OmniAb platforms for generation of diverse mono- and bispecific fully human antibodies as they look to develop first-in-class therapeutics for metabolic diseases with significant unmet needs.”

Dr. Urban A. Kiernan, the Founder and Chief Executive Officer of iMetabolic Biopharma Corporation, stated, “The willingness of the Ligand team to execute this partnership deal clearly shows their understanding of the needs and value of early stage drug discovery and development companies. Such partnerships are the driving force of innovation and we are honored and enthused to have a partner in Ligand.”

Click here to read the full press release.

The Conversation (0)
×